23 results
8-K
EX-99.1
ALDX
Aldeyra Therapeutics Inc
2 Mar 15
Regulation FD Disclosure
12:00am
Data to be presented at the Society for Inherited Metabolic Disorders
2015 Annual Meeting, March 28
NS2 Traps Aldehydes Generated by
Dry … < 0.05
Human Ocular Tissue
Human Skin Tissue
Data presented at the Society for Investigative Dermatology
2014 Annual Meeting
NS2 Summary
8-K
EX-99.1
ALDX
Aldeyra Therapeutics Inc
6 Oct 22
Regulation FD Disclosure
7:05am
† ADX-2191 Injections ** NS
RETINAL CASES & BRIEF REPORTS – JANUARY 2022 AMERICAN SOCIETY OF RETINAL SPECIALISTS 2022 MEETING Management … of Proliferative Vitreoretinopathy Alabi R, et al AMERICAN SOCIETY OF RETINAL SPECIALISTS 2022 MEETING Intravitreal methotrexate reduces reoperation rate
8-K
EX-99.1
ALDX
Aldeyra Therapeutics Inc
7 Jul 20
Aldeyra Therapeutics Announces New Drug Application (NDA) Development
8:17am
, Davis, President of PharmaLogic Development, Inc., and Chair of the Tear Film and Ocular Surface Society DEWS (Dry Eye Workshop) II Clinical Trial Design
8-K
EX-99.1
ALDX
Aldeyra Therapeutics Inc
5 Sep 14
Regulation FD Disclosure
12:00am
capital through 2015
2014 Society for Investigational Dermatology poster on novel
treatment for dry skin and eye diseases selected for Late
Breaking
8-K
EX-99.1
ALDX
Aldeyra Therapeutics Inc
5 May 22
Results of Operations and Financial Condition
7:10am
Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. The TRANQUILITY run-in cohort demonstrated statistical superiority of reproxalap over
8-K
EX-99.1
zek 2xv6g
26 Jun 18
Regulation FD Disclosure
8:13am
8-K
EX-99.1
3tv6hziq2p
6 Jun 19
Submission of Matters to a Vote of Security Holders
6:31am
8-K
EX-99.1
3iqx34
28 Feb 19
Regulation FD Disclosure
7:21am